The eighth Plasma Product Biotechnology Meeting will take place in May 2013 on the island of Lanzarote, the most easterly island of the Canarian archipelago.

The conference will bring together key opinion leaders and experts from the plasma fractionation industry, affiliated sectors and academia, for the presentation and discussion of advances in key areas related to the production of plasma products. Sessions will cover manufacturing, research and development, quality, clinical research, pathogen safety and commercial trends. The unique setting and the informal format of the sessions aims to promote open discussion of issues highlighted in the presentations. Whatever your interests, the conference offers you the opportunity to learn of new developments and trends in key scientific, technical and operational areas. In addition you can actively contribute to the scientific program, and thereby promote concepts and innovations which will underpin the future development of the plasma fractionation industry.

On behalf of the Organising Committee, I invite you to participate in the Plasma Product Biotechnology Meeting and look forward to meeting you on Lanzarote in May, 2013. Please visit the meeting Web site at www.bo-conf.com/ppb13 to register and obtain updates on event developments.

Joseph Bertolini
Chairperson
The scientific program of PPB13 will consist of both oral and poster presentations. Each session, developed by the chairperson from contributions from the participants, will reflect key issues of current importance to the industry. A central feature of these meetings is the ample opportunity to engage in informal discussions and networking during breaks and the poster session.

Session topics

Manufacturing Perspectives
Johan Vandersande, Baxter BioScience, USA
Papers presented during this session could cover many operational aspects of manufacturing plasma products including purification, filling and finishing as well as the engineering of new facilities or upgrades and expansion of existing ones. Additionally, process improvements that have been implemented such as cycle time, process efficiencies and protein recovery will definitely be considered for inclusion in the program.

Quality and Regulatory Trends
Andrea Buchacher, Octapharma PPGmbH, Austria
The session will encourage coverage of topical regulatory and quality developments in different dominions and the evaluation of new requirements. At the previous conference there was considerable focus on defining the thromboembolic potential of immunoglobulin preparations and undoubtedly this will continue. It is expected that there will be discussion on the management of process change with respect to quality systems and the ongoing adoption of the QbD concept and the appropriate statistical tools. The development of new analytical tools will continue to be highlighted as this is pivotal to characterization ensuring product comparability, efficacy and safety with ongoing process development.

Pathogen Safety
Hannelore Willkommen, Reg Affairs & Biol Safety Consulting, Germany
Challenges that may affect the safety of plasma derivatives will be discussed as well as the performance of approaches that are the basis of the high safety record of currently produced plasma derivatives. There will be a specific focus on the characterization of effective steps for virus and TSE removal and inactivation as well as investigations on the mechanism of action and influence of specific parameters impacting on achieving successful virus reduction.

Applications of Plasma Products and Clinical Developments
Juan I. Jorquera, Instituto Grifols S.A., Spain
Presentations in this session will discuss the latest results from studies of potential new plasma protein therapeutics and new applications for existing products. It is expected that in addition to efficacy data from clinical trials, presentations will include studies on preclinical evaluations, new formulation development, new options for administration and improvements in product characteristics.

Commercial and Market Trends
John Curling, John Curling Consultant AB, Sweden
The session will examine the external environment in which the plasma fractionation industry is operating in a broad sense, including commercial, market, political, consumer and regulatory issues. Talks might cover opportunities with new or currently underdeveloped markets, or developments in the political environment.

New Products & Innovations in Plasma Processing
Sami Chtourou, LFB Biotechnologies, France
This session will provide an overview of innovation in the plasma fractionation sector with respect to new product development, new therapeutic applications of existing products and developments in analytic and manufacturing options.

Session topics

Manufacturing Perspectives
Johan Vandersande, Baxter BioScience, USA
Papers presented during this session could cover many operational aspects of manufacturing plasma products including purification, filling and finishing as well as the engineering of new facilities or upgrades and expansion of existing ones. Additionally, process improvements that have been implemented such as cycle time, process efficiencies and protein recovery will definitely be considered for inclusion in the program.

Quality and Regulatory Trends
Andrea Buchacher, Octapharma PPGmbH, Austria
The session will encourage coverage of topical regulatory and quality developments in different dominions and the evaluation of new requirements. At the previous conference there was considerable focus on defining the thromboembolic potential of immunoglobulin preparations and undoubtedly this will continue. It is expected that there will be discussion on the management of process change with respect to quality systems and the ongoing adoption of the QbD concept and the appropriate statistical tools. The development of new analytical tools will continue to be highlighted as this is pivotal to characterization ensuring product comparability, efficacy and safety with ongoing process development.

Pathogen Safety
Hannelore Willkommen, Reg Affairs & Biol Safety Consulting, Germany
Challenges that may affect the safety of plasma derivatives will be discussed as well as the performance of approaches that are the basis of the high safety record of currently produced plasma derivatives. There will be a specific focus on the characterization of effective steps for virus and TSE removal and inactivation as well as investigations on the mechanism of action and influence of specific parameters impacting on achieving successful virus reduction.

Applications of Plasma Products and Clinical Developments
Juan I. Jorquera, Instituto Grifols S.A., Spain
Presentations in this session will discuss the latest results from studies of potential new plasma protein therapeutics and new applications for existing products. It is expected that in addition to efficacy data from clinical trials, presentations will include studies on preclinical evaluations, new formulation development, new options for administration and improvements in product characteristics.

Commercial and Market Trends
John Curling, John Curling Consultant AB, Sweden
The session will examine the external environment in which the plasma fractionation industry is operating in a broad sense, including commercial, market, political, consumer and regulatory issues. Talks might cover opportunities with new or currently underdeveloped markets, or developments in the political environment.

New Products & Innovations in Plasma Processing
Sami Chtourou, LFB Biotechnologies, France
This session will provide an overview of innovation in the plasma fractionation sector with respect to new product development, new therapeutic applications of existing products and developments in analytic and manufacturing options.

Monday May 13
The meeting starts with a welcome reception followed by a keynote lecture given by Julie Kim, General Manager, BioTherapeutics at Baxter BioScience U.S.A., entitled “Plasma Fractionation Today and Prospects for the Future”. This will be followed with a dinner at Casa Canarias restaurant, providing an excellent opportunity to renew contacts in the industry and make new friends.
For those arriving Sunday, there is a possibility to sign up for an optional “Volcanoes and Wine” tour, leaving at 09:30.

Tuesday May 14
The North Island tour will highlight the unique plant and geological features of Lanzarote. The tour is included in the registration fee.

Wednesday May 15
The afternoon offers an optional tour to Teguise and the Manrique Foundation.
The evening will commence with a focus lecture by Dr. Alan Lazarus from the Canadian Blood Service, Toronto, entitled “Mechanisms of Action of IVIg: What do We Really Know?” The following session – Applications of Plasma Products and Clinical Developments will include a special clinical lecture on “The New Anticoagulants and the Future of Anticoagulation” by Prof. Raffaele De Caterina, University Cardiology Division, G. d’Annunzio University, Chieti, Italy.

Thursday May 16
The Closing Dinner will be held at the Amura Restaurant in Puerto Calera with local Spanish food and entertainment providing a memorable culmination to the meeting.
### Program overview

<table>
<thead>
<tr>
<th>Monday May 13</th>
<th>Tuesday May 14</th>
<th>Wednesday May 15</th>
<th>Thursday May 16</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00–13.00</td>
<td>08.30–12.00</td>
<td>08.30–12.00</td>
<td>08.30–12.00</td>
</tr>
<tr>
<td>“Volcanoes and Wine” tour</td>
<td>Manufacturing Perspectives</td>
<td>Pathogen Safety</td>
<td>Commercial and Market Trends</td>
</tr>
<tr>
<td>Buffet lunch</td>
<td>08.30–12.00</td>
<td>Buffet lunch</td>
<td>Buffet lunch</td>
</tr>
<tr>
<td>Free time</td>
<td>12.30–16.15</td>
<td>13.00–15.30</td>
<td>Free time</td>
</tr>
<tr>
<td>16.00–19.00</td>
<td>“North Island” tour</td>
<td>15.30–17.00</td>
<td>15.00–18.00</td>
</tr>
<tr>
<td>Registration &amp; Poster setup</td>
<td>13.00–15.30 “Teguise and Manrique Foundation” tour</td>
<td>Poster Session</td>
<td>New Products &amp; Innovations in Plasma Processing</td>
</tr>
<tr>
<td>18.00–19.00</td>
<td>17.00–20.00</td>
<td>17.00–18.00</td>
<td>15.30–18.00</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>Quality &amp; Regulatory Trends</td>
<td>Focus Lecture</td>
<td>Applications of Plasma Products &amp; Clinical Developments, (including special clinical lecture)</td>
</tr>
<tr>
<td>19.00–20.00</td>
<td>20.15 Dinner</td>
<td>18.00–20.30</td>
<td>Free evening</td>
</tr>
<tr>
<td>Keynote Lecture</td>
<td>20.15 Dinner</td>
<td>18.00–20.30</td>
<td>18.50 Closing Dinner</td>
</tr>
<tr>
<td>20.15 Dinner</td>
<td>20.15 Dinner</td>
<td>18.00–20.30</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>18.00–20.30</td>
<td></td>
</tr>
</tbody>
</table>

### Important dates

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb 3, 2013</td>
<td>Last day for submission of abstracts to be considered for oral presentations</td>
</tr>
<tr>
<td>April 8, 2013</td>
<td>Early registration deadline. Last day for submission of poster abstracts to be included in the program book.</td>
</tr>
<tr>
<td>May 1, 2013</td>
<td>Final date for late registration</td>
</tr>
<tr>
<td>May 13, 2013</td>
<td>PPB13, Program and Abstract Book available</td>
</tr>
</tbody>
</table>

### Conference venue

PPB13 will be held at Melià Salinas at Costa Teguise on Lanzarote. The resort contains beautiful botanical gardens and magnificent murals. With modern accommodation and separate conference facilities, this is an ideal place for the meeting.

### Travels

Direct regular flights from many European cities are available to Arecife. The 20 minutes transportation to and from the Arecife airport and Melià Salinas, will be arranged and is included in the registration fee.
Registration

The registration fee of €1200 includes coffee breaks, receptions, special closing dinner, the Island tour and transportation to and from Arecife International Airport. After April 8, the registration fee is increased to €1500. The accompanying guest fee of €200, covers transportation, receptions, island tour and the closing dinner.

The cost of standard room per night is €200, single occupancy, and €270 double occupancy and includes meals as outlined in the program, local taxes and services. Pre- and post conference rates are based on B&B and are €140 /room/night single or double, valid 3 days before and after the meeting. Standard rooms with seaview can be booked at an additional €25 per night.

North Island tour

The North Island tour will depart at 12.30 and will head north to the Cactus Garden. The stop at los Jameos del Aqua, will include a snack lunch. The tour then continues to Mirador del Rio, with its spectacular view of the islets surrounding Lanzarote. On the return the tour goes via Haria in the center of the island and passes through the thousand palm trees valley. Arrival at Melià Salinas is at 16.15.

Optional tour

Volcanoes and Wine

Monday, May 13. The coach will depart at 09.00. It will first visit the National Park of Timanfaya which is filled with volcanoes making it appear like a lunar landscape. The surface temperature ranges from 100°C to 600°C. The tour continues to the valley of Geria, with its unique system of grapevines growing in pits hollowed out of the lava and a visit to the Bodega El Grifo winery to tour their museum and taste the wine. The coach will return to Melià Salinas by 13.00. Cost: €52 per person; Minimum number of people: 15.

Teguise and Manrique Foundation

Wednesday May 15. The coach will depart at 13.00 and will first visit Teguise, the ancient capital of Lanzarote. The town has a unique charm with beautiful wood and stone carvings around doors and windows. The tour will make a brief stop at the Monument of the Farmer, before visiting Manrique Foundation, the original home of the artist and architect César Manrique. The coach will return to Melià Salinas by 15.30 in time for the poster session. Cost: €35 per person; Minimum number of people: 15.

Abstract submission

An abstract should include: title, authors, authors’ affiliation and full address of the person presenting the abstract. Last day for submission of abstracts to be considered for oral presentation is February 3, 2013. We would like to place the talks on the password protected website after the conference, so please ensure that you address any legal issues regarding your talk beforehand.

Register now and save

Registrations before April 8, 2013 are eligible for the discount fee of €1200. Register online or mail or fax the enclosed form.

The quoted registration fee exclude VAT. All participants from outside the EU will pay the quoted fee. Participants from within the EU must state their VAT number to be able to exclude VAT. Swedish participants must pay 25% VAT.

Instructions for payment

By bank transfer in Euro (€)
Account number: 1830 27 07082 EUR
Account name: B.O. Conference Service
Bank name: Nordea Bank AB Box 455, SE-751 06 Uppsala, Sweden
IBAN: SE12 3000 0000 0183 0270 7082
Swiftcode: NDEASESS

Using credit card
VISA, MasterCard/EuroCard and American Express are accepted. Please, supply the relevant information by registering online on our secure server. You can also fill out this form and fax it to the Secretariat (+46 702 73 36 43).

Cancellation

If unable to attend following a registration, a colleague may substitute at any time. Please inform us in advance.

In case of cancellation the total payment minus 15% (administration fee) will be refunded. Request for cancellation must be received in writing before April 15, 2013. All refunds will be processed after the meeting.

Meeting information and updates are available on our Web site: www.bo-conf.com/ppb13
# Registration

You can register online. Alternatively, complete the following details and submit by fax or mail to the Secretariat. If all details are not provided your registration will be considered preliminary and will not be processed unless all requested information is provided.

<table>
<thead>
<tr>
<th>Name</th>
<th>State/Zip</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affiliation</td>
<td>Country</td>
</tr>
<tr>
<td>Department</td>
<td>Phone</td>
</tr>
<tr>
<td>Street</td>
<td>Fax</td>
</tr>
<tr>
<td>City</td>
<td>E-mail</td>
</tr>
</tbody>
</table>

**Registration fee**

- Normal registration fee: €1200
- Addition for late registration: €300
- Accompanying guest: €200

**Accommodation**

- Single occupancy: €200 per night
- Double occupancy: €270 per night
- Pre/post meeting: €140 per night
- Add seaview: €25 per night

**Optional tour**

- Volcanoes and Wine: €52
- Teguise and Manrique: €35

**Arrival**

- Date of arrival to Lanzarote
- Flight no. / Arrival time

**Departure**

- Date of departure from Lanzarote
- Flight no. / Departure time

**Method of payment**

- Visa
- Master card/Eurocard
- Amexco
- Bank to bank transfer
- Other

**Emergency contact details**

- Name
- Phone

**Total payable**

Fees + Accommodation + Optional tour (€) _

**Authorization**

- Signature
- Date

---

* VAT number is required for participants from within EU, 25% VAT will be added for Swedish participants.
The Eighth Plasma Product Biotechnology Meeting is jointly sponsored by CSL Biotherapies, Melbourne, Australia and GE Healthcare Life Sciences, Uppsala, Sweden.